Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OKYO Pharma Limited - Ordinary Shares (NQ:OKYO)

2.050 +0.010 (+0.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 285,936
Open 2.070
Bid (Size) 2.000 (300)
Ask (Size) 2.050 (300)
Prev. Close 2.040
Today's Range 1.996 - 2.185
52wk Range 1.010 - 3.349
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Successful Type C Meeting with the FDA
FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size and development approach 
From OKYO Pharma LTD
Via GlobeNewswire

Performance

YTD
-8.1%
-8.1%
1 Month
-8.1%
-8.1%
3 Month
-24.1%
-24.1%
6 Month
-34.3%
-34.3%
1 Year
+93.4%
+93.4%

More News

Read More
News headline image
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Stock Rises After Company Outlines Development Pathway For Neuropathic Corneal Pain Drug ↗
Via Stocktwits
Friday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Ring the Opening Bell at Nasdaq
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Chairman and Founder Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Chairman and Founder Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Chairman and Founder Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Present at OIS XV in San Diego
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Present at BIO-Europe 2025 in Vienna
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Chairman and Founder Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited
Via ACCESS Newswire
News headline image
OKYO Pharma to Present at the Bio International Convention
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire

Frequently Asked Questions

Is OKYO Pharma Limited - Ordinary Shares publicly traded?
Yes, OKYO Pharma Limited - Ordinary Shares is publicly traded.
What exchange does OKYO Pharma Limited - Ordinary Shares trade on?
OKYO Pharma Limited - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for OKYO Pharma Limited - Ordinary Shares?
The ticker symbol for OKYO Pharma Limited - Ordinary Shares is OKYO on the Nasdaq Stock Market
What is the current price of OKYO Pharma Limited - Ordinary Shares?
The current price of OKYO Pharma Limited - Ordinary Shares is 2.050
When was OKYO Pharma Limited - Ordinary Shares last traded?
The last trade of OKYO Pharma Limited - Ordinary Shares was at 01/30/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.